Revenue for the three-quarter period rose to ¥597 million, up from the ¥563 million recorded during the same timeframe a year earlier. Despite this top-line growth, the company’s bottom line was weighed down by non-operating expenses, causing the net loss to deepen from the ¥717 million deficit reported in the previous year.
In section Market Quotes
OncoTherapy Science Net Loss Widens to ¥783 Million
Japanese biotechnology firm OncoTherapy Science Inc. reported a widened net loss of ¥783 million for the nine months ended Dec. 31, 2024, as the company struggled to translate modest revenue growth into improved profitability.
Shifting Margins and Per-Share Data
According to the company's financial filing, the operating loss showed a marginal improvement, narrowing to ¥694 million from ¥698 million. However, the pretax loss expanded to ¥720 million, signaling continued pressure on the firm’s financial health as it navigates the capital-intensive drug discovery sector.Key metrics from the nine-month report include:
- Total Revenue: ¥597 million
- Net Loss: ¥783 million
- Loss per Share: ¥2.52
Comments (0)
No comments yet. Be the first!